Glucotrack, Inc., a medical device company focused on an implantable continuous blood glucose monitor (CBGM), reported no material change in risk factors but disclosed receipt of a Nasdaq Staff Determination to delist its stock due to sustained low bid price. The company is accelerating discussions with the FDA to initiate a U.S. clinical trial program for the CBGM, aiming for regulatory approval in a market dominated by established CGM providers. Despite promising preclinical data showing sensor longevity up to three years, Glucotrack faces significant operational risks related to clinical trials, regulatory uncertainty, and liquidity constraints. The company holds ISO 13485 certification and has strategic manufacturing partnerships but must resolve key regulatory milestones and financial hurdles for sustained growth.